China Contract Research Organization (CRO) Industry Report, 2010-2011
  • July/2011
  • Hard Copy
  • USD $1,800
  • Pages:58
  • Single User License
    (PDF Unprintable)       
  • USD $1,700
  • Code: HM003
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $2,500
  • Hard Copy + Single User License
  • USD $2,000
      
Under the circumstances of increasingly high R&D costs of new drugs worldwide, the contract research organization (CRO) industry has developed rapidly in recent years thanks to its advantages of shortening the R&D cycle and cost saving. In 2010, the global market size of CRO achieved RMB36 billion, which undertook nearly one third of the R&D of new drugs. CRO industry started relatively late in China, and still in its initial stage with only a few business varieties. In China, the market size of CRO was merely USD2.6 billion (about RMB16.9 billion) in 2010. However, with rapid development, currently there are almost 500 CRO enterprises in China.

Although there are many CRO enterprises in China, large-scale enterprises are less than 10 companies. WuXi AppTec and ShangPharma, two NYSE listed companies, are the largest CRO enterprises in China. WuXi AppTec is the leading enterprise in domestic CRO industry, whose clients include 9 of the top 10 pharmaceutical enterprises worldwide. In Jan. 2008, it successfully acquired AppTec Laboratory Services Inc. for USD151 million, initiating the overseas expansion of Chinese CRO enterprises.

ShangPharma is the second largest CRO enterprise in China. It has over 100 enterprise and academic research institution clients, including the top 10 pharmaceutical enterprises in the world. With the aim to enhance its R&D strength, ShangPharma plans to construct cGMP base and laboratory service building with the funds raised from its IPO in 2010.

Currently, most of the CRO enterprises can only accomplish a single section in the R&D process, therefore, in order to complete the industry chain and enhance the competitiveness, M&A and setting up industry alliance has become a trend in China’s CRO industry. From 2007 to Apr. 2011, there were at least 6 M&A cases in the CRO industry of China. As of Apr. 2011, there were five biopharmaceutical CRO industry alliances in China, including Alliance of Bio-Box Outsourcing, China, Zhongguancun Bio-pharmaceutical R&D Outsourcing Alliance, Shanghai Pudong Bio-Pharmaceutical R&D Outsourcing Service Alliance, CROSA and Chengdu Bio-pharmaceutical R&D Outsourcing Alliance. Having witnessed the advantage of CRO alliances in China, foreign companies participated in as well. For instance, the European company NovaSecta joined CROSA.  

M&A Cases of CRO Industry in China, 2007-2011
201107047.gif
Source: ResearchInChina
1.Overview of CRO Industry 
1.1 Definition & Classification
1.2 Industry Background

2. Development Environment of CRO Industry in China
2.1 International Environment
2.2 Industry Environment
2.3 Policy Environment

3. Market Analysis of CRO Industry in China
3.1 Status Quo
3.2 Market Size
3.3 Competition Pattern
3.4 Prospects
3.4.1 Specialized Division of Labor 
3.4.2 Low Entry Barriers
3.4.3 Huge Demand
3.5 CRO Industry Alliances in China
3.5.1 ABO
3.5.2 Zhongguancun Bio-pharmaceutical R&D Outsourcing Alliance
3.5.3 Shanghai Pudong Bio-Pharmaceutical R&D Outsourcing Service Alliance 
3.5.4 CROSA
3.5.5 Chengdu Bio-pharmaceutical R&D Outsourcing Alliance 

4. Regional Market
4.1 Beijing
4.1.1 Pharmaceutical Manufacturing with Steady Growth
4.1.2 G20 Enterprises have Become the Core Strength of Industrial Development
4.1.3 R&D Services Industry Presents Prominent Contribution, with ABO Union Becoming an Important Force.
4.2 Shanghai
4.2.1 State Biotech & Pharmaceutical Industrial Base (Shanghai) (Zhangjiang Drug Valley)
4.3 Nanjing
4.3.1 Market Advantage 
4.3.2 Development Prospects

5. Key CRO Enterprises Worldwide
5.1 COVANCE
5.1.1 Profile
5.1.2 Operation
5.1.3 Business in China
5.2 PAREXEL INTERNATIONAL
5.2.1 Profile
5.2.2 Business in China
5.3 PPD
5.3.1 Profile
5.3.2 Business in China
5.4 Quintiles Transnational
5.4.1 Profile
5.4.2 Business in China
5.5 Charles River Labs (CRL)
5.5.1 Profile
5.5.2 Business in China
5.6 Asymchem Inc
5.6.1 Profile
5.6.2 Asymchem Laboratories (Tianjin) Co. Ltd. 
5.6.3 Asymchem Life Science (Tianjin) Co., Ltd.
5.7 MDS Inc.
5.7.1 Profile
5.7.2 MDS Pharma Services (China) Inc.

6.Key CRO Enterprises in China
6.1 WuXi AppTec Co., Ltd.
6.1.1 Profile
6.1.2 Operation
6.1.3 Business Structure
6.1.4 Development
6.2 ShangPharma Corp
6.2.1 Profile
6.2.2 Operation
6.2.3 Development
6.2.4 Shanghai ChemPartner Co. Ltd
6.2.5 Shanghai ChemExplorer Co. Ltd
6.2.6 Chengdu China Gateway Pharmaceutical Development Co. Ltd
6.3 Venturepharm Laboratories Limited
6.3.1 Profile
6.3.2 Operation
6.3.3 Development
6.4 Sundia MediTech Co., Ltd
6.5 Chemizon (Beijing) Pharma-Tech Co., Ltd
6.6 Excel PharmaStudies Co. Ltd
6.7 Tigermed Pharma-Tech Co., Ltd
Classification of CRO
Market Size and Growth Rate of Global CRO, 2007-2010
Global Key CRO Organizations and Their Business 
Industrial Sales Output Value and Growth Rate of Pharmaceutical Manufacturing Industry in China, 2008-Apr. 2011
Output Value of New Products of Pharmaceutical Manufacturing Industry in China, 2008-2010 
Classification of Chinese CRO Companies (by Business)
Market Size and Growth Rate of CRO in China, 2007-2010
Key M&A Cases of CRO Industry in China, 2007-2011
Orders and Revenue of ABO Union and Proportions in International Orders ,2008-2010
Key Members and Unique Services of ABO Union
Sponsor of Zhongguancun CRO Union (in no particular order)
Biopharmaceutical CRO Companies in Shanghai Pudong New Area
CRO Service Chain of Shanghai Pudong Zhangjiang 
Operating Income and Total Profit of Beijing Pharmaceutical Industry by Sector, 2010
Advantageous Fields of Beijing CRO Services
Platform Edge of Zhangjiang Drug Valley 
List of Major CRO Companies of Zhangjiang Drug Valley, Shanghai 
Industry Advantages of CRO Nanjing 
Operating Income and Gross Margin of Covance, 2007-2010
Operating Income of Covance (by Business), 2008-2010
Operating Income of PAREXEL, 2007-2010
Revenue of PAREXEL Worldwide (by Region), 2008-2010 
Operating Income of PPD, 2007-2010
Sales of CRL, 2007-2010
Companies of Asymchem Inc in China and Major Business
Operation of Asymchem Laboratories (Tianjin), 2008 and Jan. 2009- May 2009
Operation of Asymchem Life Science (Tianjin), 2008 
Major Facilities of WuXi AppTec
Sales and Gross Margin of WuXi AppTec, 2008-2010
Sales of WuXi AppTec (By Business), 2010
Main Bases of ShangPharma Corp
Net Income and Gross Profit of ShangPharma Corp, 2008-2010
Net Income of ShangPharma Corp Worldwide (by Region), 2007-2009
Revenue and Gross Profit of Venturepharm Laboratories Limited, 2007- Jan.- Mar.2011
Operation of Venturepharm Laboratories Limited, 2007-Jan.- Mar.2011
Patents Applied by Venturepharm Laboratories Limited
Strength of Excel PharmaStudies
Main Clients of Tigermed Pharma-Tech

China Dental Industry Report, 2014-2018

Oral industry refers to the medical industry chain on the basis of oral medical consumption, mainly covering oral medical apparatus (equipment and consumables) and oral medical services. As reform of ...

China Medical Monitor Industry Report, 2014-2017

With advancement of medical reform, improvement of spending power, and enhancement of health care consciousness, China’s medical monitor industry is gradually expanding. During 2007-2013, the market s...

China Independent Clinical Laboratory Industry Report, 2014-2017

The independent clinical laboratory industry starts relatively late in China, featuring a limited overall size but high-speed development. In 2013 the independent clinical laboratory market size there...

China Interventional Cardiovascular Device Industry Report,2014-2017

The prevalence of cardiovascular disease in China impacted by accelerated aging of population and changes in consumption concept, dietary habit, way of working and other lifestyles has been growing ye...

China PTCA Balloon Market Investment Report, 2014-2016

PTCA balloon, as a indispensable medical device in percutaneous coronary intervention (PCI), serves not only as a delivery system for stent, but also as a device for pre-/post-stent dilatations. There...

China Orthopedic Instrument Industry Report, 2014-2017

Benefiting from accelerated aging population and rising proportion of reimbursement for medical expenses, the Chinese orthopedic instrument market demand has been effectively released, with its scale ...

China Hospital Development and Investment Report, 2014-2017

China hospital industry has been developing quickly in recent years, thanks to the market demand stimulus and steady progress in health care reform. The number of Chinese hospitals grew at a CAGR of 6...

China Diagnostic Reagent Industry Report, 2013-2016

With the accelerated aging of the Chinese population, the increase of personal health expenditure as well as the improved medical care facilities and government health care system, China diagnostic re...

China Hemodialysis Equipment Import and Export Report, 2013-2016

Hemodialysis equipment is the most widely used treatment apparatus in blood purification, primarily targeting patients with acute or chronic renal failure.The Chinese hemodialysis equipment market sho...

Global and China Hemodialysis Industry Report, 2013-2016

Hemodialysis, also known as artificial kidney, is a type of blood purification technology, primarily applicable to the treatment of patients with rental failure. In 2013, the global number of patient...

China Portable Medical Equipment Industry Report, 2013-2016

With the synergy of favorable policies, improvement in living standards and healthcare awareness raising, China’s portable medical device industry has shown rapid development in recent years, with mar...

China Medical Informatization Industry Report,2013-2016

Under the impetus of multiple favorable policies and market demand, China's medical informatization industry has entered a rapid development stage in recent years. As of the first half of 2013, manage...

China Aged Care Industry Report, 2013-2016

Currently, China has entered the accelerated aging period. China’s population aged 65 and above reached 131.61 million in 2013, accounting for 9.7% of total population; and the proportion will rise to...

China Pharmaceutical Equipment Industry Report, 2013-2016

After decades of development, China has become a major producer of pharmaceutical equipment in the world. Since 2010, affected by the new GMP certification and other factors, the revenue and total pro...

China Dental Industry Report, 2013-2016

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental appliances (equipments and consumables), dental medical services, etc. with...

China Medical Monitor Industry Report, 2013-2015

In 2007-2011, the Chinese medical monitor market size rose from RMB1.16 billion to RMB3.08 billion at a CAGR of 27.8%. In 2012, the figure reached RMB3.86 billion, a year-on-year increase of 25.3%, of...

China Interventional Cardiovascular Device Industry Report, 2013-2015

With the accelerated aging, the prevalence of cardiovascular diseases in China increased year by year. According to statistics of National Health and Family Planning Commission of the People’s Republi...

China Diagnostic Reagent Industry Report, 2013-2015

Driven by huge population base, intensified aging and many favorable policies, China diagnostic reagent industry has been developing rapidly. In 2008-2012, the diagnostic reagent market size presented...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统